Assertio Therapeutics Inc

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Assertio Therapeutics Inc reports stellar Q4 performance and growth outlook

Assertio Therapeutics Inc (ASRT) delivered a robust Q4 performance with significant revenue and profit growth, despite facing challenges like supply issues.
The company's strategic focus on marketing, product development, and business expansion highlights a commitment to long-term success and shareholder value.
With a positive outlook for 2023 and a strong foundation in place, ASRT is poised for continued growth and value creation in the pharmaceutical market.

Assertio Therapeutics Inc (ASRT) reports robust Q1 results and raises 2023 guidance

Assertio Therapeutics Inc (ASRT) demonstrated solid financial performance in Q1 2023, with strong sales growth and improved profitability.
The company's strategic execution and upcoming acquisitions signal a positive outlook for future growth and expansion.
While facing integration challenges and market competition, Assertio's focus on product sales and operational efficiency bodes well for sustained success.

Assertio Therapeutics reports strong Q2 growth amidst generic competition

Assertio's Q2 performance showcased growth driven by key products and the acquisition of Spectrum Pharmaceuticals, positioning the company for future success.
While facing challenges from generic competition and operational expenses, Assertio remains focused on defending market share and creating shareholder value.
Management's confidence in overcoming short-term obstacles underscores a proactive approach to navigating market dynamics and driving growth.

Assertio Therapeutics Inc reports resilient Q3 performance amidst challenges

Assertio Therapeutics Inc navigated challenges in Q3 2023 with resilience, reporting positive financial metrics and improved liquidity.
New management changes and a focus on market access signal the company's commitment to driving growth and optimizing operations.
Despite lower sales for certain products, Assertio's strategic initiatives and financial performance position it well for future opportunities.
Analyst inquiries during the call highlighted areas for improvement and growth, indicating a proactive approach to addressing market dynamics.

Assertio Therapeutics reports robust Q4 results and outlines growth plans

Assertio Therapeutics Inc (ASRT) demonstrated strong financial performance in Q4 2023, driven by robust sales and positive EBITDA.
The company's strategic focus on Rolvedon's growth, profitability optimization, and future acquisitions positions it well for continued success.
While facing challenges from generic competition and operational issues, Assertio is poised to capitalize on growth opportunities and drive value creation.

Assertio Therapeutics Inc meets Q1 targets, eyes growth opportunities

Assertio Therapeutics Inc's Q1 2024 showcased strong sales performance, cost management, and cash generation. Despite challenges in generic competition and CEO transition, the company remains focused on growth opportunities.

Assertio Therapeutics reports solid Q2 results and projects growth

Assertio Therapeutics Inc (ASRT) demonstrated financial stability, growth potential, and resilience in the face of market challenges during Q2 2024.
The company's strategic focus on key products like Rolvedon and effective cost management strategies position it well for future success and profitability.
Maintaining guidance for 2024 and leveraging opportunities for growth underscore Assertio's commitment to delivering value to shareholders and stakeholders.

Assertio Therapeutics reports stable Q3 performance amid ROLVEDON transition

Assertio Therapeutics demonstrated stable financial performance and operational efficiency in Q3 2024, positioning the company for growth amidst challenges.
The company's focus on ROLVEDON and governance enhancements signal a strategic shift towards innovation and stakeholder value creation.
While facing challenges such as declining product sales and financial constraints, Assertio remains resilient and poised to capitalize on opportunities for growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings, Inc.'s (ASRT) CEO Daniel Peisert on Q4 2021 Results - Earnings Call Transcript

Assertio (ASRT) delivered earnings and revenue surprises of -16.67% and 8.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Q4 Earnings Lag Estimates

$32.2 Million Fourth Quarter Net Product Sales, a 7% Increase from Fourth Quarter 2020  and $109.4 Million Full Year Net Product Sales

Assertio Reports Fourth Quarter and Full Year 2021 Financial Results

Catalyst Pharmaceuticals

Chinook Therapeutics

Sigilon Therapeutics

Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.

4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry

LAKE FOREST, Ill., March 02, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release fourth quarter and full year 2021 financial results on Wednesday, March 9, 2022, before the open of markets. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 9:00 a.m. eastern time.

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results Before the Opening of Markets on Wednesday, March 9, 2022

Assertio (ASRT) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Assertio (ASRT) Shows Fast-paced Momentum But Is Still a Bargain Stock

After years of losses and declining revenues, new management was brought in a year ago. Assertio looks almost entirely different than two years ago.

Assertio: A Turnaround Where Almost Everything Just Changed

The company has successfully shedded its opioid businesses, $900M+ in debt and slashed well over half of its OpEx, increasing guidance three times in a year. Having gotten rid of its sales force by financial necessity and pandemic force, their digital only strategy, which looked like a huge gamble, is starting to look like it's working.

Assertio's Digital Strategy Looks To Be Paying Off

Assertio (ASRT) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Despite Fast-paced Momentum, Assertio (ASRT) Is Still a Bargain Stock

NEW YORK, Dec. 27, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Assertio Holdings, Inc. (NASDAQ: ASRT). If you are a shareholder of Assertio Holdings, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: http://pjlfirm.com/assertio-holdings-inc/ You may also contact Robert H.

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Assertio Holdings, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

Investors need to pay close attention to Assertio (ASRT) stock based on the movements in the options market lately.

Do Options Traders Know Something About Assertio (ASRT) Stock We Don't?

Antares Pharma Inc (NASDAQ: ATRS) divested Otrexup (methotrexate) injection to treat rheumatoid arthritis to a subsidiary of Assertio Holdings Inc (NASDAQ: ASRT) for $44 million inclusive of Otrexup WIP and finished inventory.  Under the asset purchase agreement terms, Antares will receive an initial payment of $18.0 million at closing plus two additional time-based payments totaling $26.0 million in 2022.

Assertio Shares Gain After Buying Antares' Rheumatoid Arthritis Treatment For $44M

Trailing 12 Month Reported Revenues of Otrexup Were $15.5 Million

Assertio Holdings, Inc. Announces the Acquisition of Otrexup® (methotrexate) a Drug Device Combination from Antares Pharma, Inc.

LAKE FOREST, Ill., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that on October 28, 2021, the Superior Court of the State of California for the County of Alameda (the “Court”) preliminarily approved a settlement agreement (the “Settlement”) resolving three shareholder derivative lawsuits involving the Company's subsidiary, Assertio Therapeutics, Inc. (“Assertio Therapeutics”). The Settlement was previously disclosed in the Company's quarterly report on Form 10-Q for the period ended September 30, 2021.

Assertio Holdings, Inc. Announces Preliminary Court Approval of Shareholder Derivative Settlement

The stock price of Assertio Holdings Inc (NASDAQ: ASRT) increased by over 27% during intraday trading today. This is why it happened.

Assertio Holdings (ASRT) Stock: Why The Price Jumped Today

Assertio Holdings Inc (NASDAQ: ASRT) posted Q3 sales of $25.9 million, down 23% Y/Y, but surpassed the consensus of $22.04 million. Assertio's restructuring plan resulted in cost savings of $40.0 million in 2021.

Assertio Posts Higher Profitability In Q3 Despite Lower Revenues

Assertio Holdings' (ASRT) CEO Dan Peisert on Q3 2021 Results - Earnings Call Transcript

Assertio (ASRT) delivered earnings and revenue surprises of 300.00% and 15.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates

Assertio (ASRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Assertio (ASRT) Q3 Earnings Expected to Decline

LAKE FOREST, Ill., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it will release third quarter 2021 financial results on Thursday, November 4, 2021, after the close of markets. Following the release of its financial results, Assertio's management will host a conference call beginning at 4:30 p.m. eastern time.

Assertio Holdings, Inc. to Report Third Quarter 2021 Financial Results After the Close of Markets on Thursday, November 4, 2021

LAKE FOREST, Ill., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or “the Company”) (NASDAQ: ASRT) today announced that the Company's Chief Executive Officer, Dan Peisert, and Chief Financial Officer, Paul Schwichtenberg, will present and host individual meetings with investors at the following events:

Assertio Holdings, Inc. to Participate in Upcoming Investor Events

Assertio Holdings, Inc. (ASRT) CEO Dan Peisert on Q2 2021 Results - Earnings Call Transcript

Reported Net Product Sales of $24.8 Million

Assertio Reports Second Quarter 2021 Financial Results

Assertio (ASRT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

LAKE FOREST, Ill., June 04, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”).   Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement and this matter is now closed.

News for Assertio Therapeutics Inc Stock (ASRT)